BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 26905262)

  • 21. Interaction between the estrogen receptor and fibroblast growth factor receptor pathways in non-small cell lung cancer.
    Siegfried JM; Farooqui M; Rothenberger NJ; Dacic S; Stabile LP
    Oncotarget; 2017 Apr; 8(15):24063-24076. PubMed ID: 28445992
    [TBL] [Abstract][Full Text] [Related]  

  • 22. FGFR1 mRNA and protein expression, not gene copy number, predict FGFR TKI sensitivity across all lung cancer histologies.
    Wynes MW; Hinz TK; Gao D; Martini M; Marek LA; Ware KE; Edwards MG; Böhm D; Perner S; Helfrich BA; Dziadziuszko R; Jassem J; Wojtylak S; Sejda A; Gozgit JM; Bunn PA; Camidge DR; Tan AC; Hirsch FR; Heasley LE
    Clin Cancer Res; 2014 Jun; 20(12):3299-309. PubMed ID: 24771645
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rationale for treatment of metastatic squamous cell carcinoma of the lung using fibroblast growth factor receptor inhibitors.
    Göke F; Franzen A; Menon R; Goltz D; Kirsten R; Boehm D; Vogel W; Göke A; Scheble V; Ellinger J; Gerigk U; Fend F; Wagner P; Schroeck A; Perner S
    Chest; 2012 Oct; 142(4):1020-1026. PubMed ID: 22499828
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fibroblast growth factor receptor 1 gene amplification in pancreatic ductal adenocarcinoma.
    Lehnen NC; von Mässenhausen A; Kalthoff H; Zhou H; Glowka T; Schütte U; Höller T; Riesner K; Boehm D; Merkelbach-Bruse S; Kirfel J; Perner S; Gütgemann I
    Histopathology; 2013 Aug; 63(2):157-66. PubMed ID: 23808822
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial.
    Pearson A; Smyth E; Babina IS; Herrera-Abreu MT; Tarazona N; Peckitt C; Kilgour E; Smith NR; Geh C; Rooney C; Cutts R; Campbell J; Ning J; Fenwick K; Swain A; Brown G; Chua S; Thomas A; Johnston SRD; Ajaz M; Sumpter K; Gillbanks A; Watkins D; Chau I; Popat S; Cunningham D; Turner NC
    Cancer Discov; 2016 Aug; 6(8):838-851. PubMed ID: 27179038
    [TBL] [Abstract][Full Text] [Related]  

  • 26. FGFR1 promotes the stem cell-like phenotype of FGFR1-amplified non-small cell lung cancer cells through the Hedgehog pathway.
    Ji W; Yu Y; Li Z; Wang G; Li F; Xia W; Lu S
    Oncotarget; 2016 Mar; 7(12):15118-34. PubMed ID: 26936993
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fibroblast Growth Factor Receptors as Targets for Radiosensitization in Head and Neck Squamous Cell Carcinomas.
    Fisher MM; SenthilKumar G; Hu R; Goldstein S; Ong IM; Miller MC; Brennan SR; Kaushik S; Abel L; Nickel KP; Iyer G; Harari PM; Kimple RJ; Baschnagel AM
    Int J Radiat Oncol Biol Phys; 2020 Jul; 107(4):793-803. PubMed ID: 32298810
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of FGFR inhibitors TKI258, BGJ398 and AZD4547 on breast cancer cells in 2D, 3D and tissue explant cultures.
    Kähkönen TE; Toriseva M; Petruk N; Virta AR; Maher A; Eigéliené N; Kaivola J; Boström P; Koskivuo I; Nees M; Tuomela JM; Ivaska KK; Härkönen PL
    Cell Oncol (Dordr); 2021 Feb; 44(1):205-218. PubMed ID: 33119860
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cisplatin Increases Sensitivity to FGFR Inhibition in Patient-Derived Xenograft Models of Lung Squamous Cell Carcinoma.
    Weeden CE; Holik AZ; Young RJ; Ma SB; Garnier JM; Fox SB; Antippa P; Irving LB; Steinfort DP; Wright GM; Russell PA; Ritchie ME; Burns CJ; Solomon B; Asselin-Labat ML
    Mol Cancer Ther; 2017 Aug; 16(8):1610-1622. PubMed ID: 28611104
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting the heparin-binding domain of fibroblast growth factor receptor 1 as a potential cancer therapy.
    Ling L; Tan SK; Goh TH; Cheung E; Nurcombe V; van Wijnen AJ; Cool SM
    Mol Cancer; 2015 Jul; 14():136. PubMed ID: 26201468
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic role of FGFR1 amplification in early-stage non-small cell lung cancer.
    Cihoric N; Savic S; Schneider S; Ackermann I; Bichsel-Naef M; Schmid RA; Lardinois D; Gugger M; Bubendorf L; Zlobec I; Tapia C
    Br J Cancer; 2014 Jun; 110(12):2914-22. PubMed ID: 24853178
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of Pharmacodynamic Transcript Biomarkers in Response to FGFR Inhibition by AZD4547.
    Delpuech O; Rooney C; Mooney L; Baker D; Shaw R; Dymond M; Wang D; Zhang P; Cross S; Veldman-Jones M; Wilson J; Davies BR; Dry JR; Kilgour E; Smith PD
    Mol Cancer Ther; 2016 Nov; 15(11):2802-2813. PubMed ID: 27550940
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel FGFR inhibitor ponatinib suppresses the growth of non-small cell lung cancer cells overexpressing FGFR1.
    Ren M; Hong M; Liu G; Wang H; Patel V; Biddinger P; Silva J; Cowell J; Hao Z
    Oncol Rep; 2013 Jun; 29(6):2181-90. PubMed ID: 23563700
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Insight into resistance mechanisms of AZD4547 and E3810 to FGFR1 gatekeeper mutation via theoretical study.
    Liang D; Chen Q; Guo Y; Zhang T; Guo W
    Drug Des Devel Ther; 2017; 11():451-461. PubMed ID: 28255231
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preselection of Lung Cancer Cases Using FGFR1 mRNA and Gene Copy Number for Treatment With Ponatinib.
    Ng TL; Yu H; Smith DE; Boyle TA; York ER; Leedy S; Gao D; Aisner DL; Van Bokhoven A; Heasley LE; Hirsch FR; Camidge DR
    Clin Lung Cancer; 2019 Jan; 20(1):e39-e51. PubMed ID: 30297175
    [TBL] [Abstract][Full Text] [Related]  

  • 36. FGFR1-4 RNA-Based Gene Alteration and Expression Analysis in Squamous Non-Small Cell Lung Cancer.
    Moes-Sosnowska J; Skupinska M; Lechowicz U; Szczepulska-Wojcik E; Skronska P; Rozy A; Stepniewska A; Langfort R; Rudzinski P; Orlowski T; Popiel D; Stanczak A; Wieczorek M; Chorostowska-Wynimko J
    Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142417
    [TBL] [Abstract][Full Text] [Related]  

  • 37. FGFR1 emerges as a potential therapeutic target for lobular breast carcinomas.
    Reis-Filho JS; Simpson PT; Turner NC; Lambros MB; Jones C; Mackay A; Grigoriadis A; Sarrio D; Savage K; Dexter T; Iravani M; Fenwick K; Weber B; Hardisson D; Schmitt FC; Palacios J; Lakhani SR; Ashworth A
    Clin Cancer Res; 2006 Nov; 12(22):6652-62. PubMed ID: 17121884
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer.
    André F; Bachelot T; Campone M; Dalenc F; Perez-Garcia JM; Hurvitz SA; Turner N; Rugo H; Smith JW; Deudon S; Shi M; Zhang Y; Kay A; Porta DG; Yovine A; Baselga J
    Clin Cancer Res; 2013 Jul; 19(13):3693-702. PubMed ID: 23658459
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Amplification of FGFR1 gene and expression of FGFR1 protein is found in different histological types of lung carcinoma.
    Sousa V; Reis D; Silva M; Alarcão AM; Ladeirinha AF; d'Aguiar MJ; Ferreira T; Caramujo-Balseiro S; Carvalho L
    Virchows Arch; 2016 Aug; 469(2):173-82. PubMed ID: 27194548
    [TBL] [Abstract][Full Text] [Related]  

  • 40. FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR inhibitor AZD4547.
    Xie L; Su X; Zhang L; Yin X; Tang L; Zhang X; Xu Y; Gao Z; Liu K; Zhou M; Gao B; Shen D; Zhang L; Ji J; Gavine PR; Zhang J; Kilgour E; Zhang X; Ji Q
    Clin Cancer Res; 2013 May; 19(9):2572-83. PubMed ID: 23493349
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.